Filtered By:
Condition: Stroke
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 855 results found since Jan 2013.
COVID-19 Can Cause New Cholesterol Problems. What to Know
Not long after the start of the global coronavirus pandemic, it was apparent that many people infected with SARS-CoV-2 were developing persistent and, in some cases, debilitating health problems. Now known widely as post-Covid syndrome or Long COVID, the most common symptoms of this condition are fatigue, attention problems, headaches, muscle or joint pain, and weakness. But those are just the start. Medical researchers have also linked SARS-CoV-2 to lingering complications in multiple organs and systems, and some recent work has found that new-onset cholesterol problems may be an under-recognized but common complication o...
Source: TIME: Health - May 30, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Viruses, Vol. 15, Pages 1235: Ischaemic Stroke Occurring in a Patient Treated with Monoclonal Antibodies for COVID-19
In conclusion, among several side effects that have been described during the treatment of COVID-19 with sotrovimab, ischaemic stroke was not reported. Therefore, we here report a rare case of ischaemic stroke with early clinical manifestation after the administration of sotrovimab for the treatment of moderate COVID-19 in an immunocompromised patient for the first time.
Source: Viruses - May 25, 2023 Category: Virology Authors: Antonio Lobasso Ciro di Gennaro Maria Rita Poggiano Antonio Vasta Raffaele Angelo Nicola Ranucci Roberto Lobianco Anna Giacoma Tucci Enrico Cavagli à Pierpaolo Di Micco Tags: Case Report Source Type: research
Observational Study of Patients Hospitalized With Neurologic Events After SARS-CoV-2 Vaccination, December 2020-June 2021
Discussion
All cases in this study were determined to have at least 1 risk factor and/or known etiology accounting for their neurologic syndromes. Our comprehensive clinical review of these cases supports the safety of mRNA COVID-19 vaccines.
Source: Neurology Clinical Practice - May 25, 2023 Category: Neurology Authors: Kim, C. Y., McNeill, E. N., Young, C., King, F., Clague, M., Caldwell, M., Boruah, A., Zucker, J., Thakur, K. T. Tags: Autoimmune diseases, Post-infectious, Inclusion, Diversity, Equity, Anti-racism, and Social Justice (IDEAS), COVID-19 Research Article Source Type: research
Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature
Ther Adv Drug Saf. 2023 May 21;14:20420986231165674. doi: 10.1177/20420986231165674. eCollection 2023.ABSTRACTAmid the coronavirus disease 2019 (COVID-19) pandemic, massive immunization campaigns became the most promising public health measure. During clinical trials, certain neurological adverse effects following immunization (AEFIs) were observed; however, acceptable safety profiles lead to emergency authorization for the distribution and use of the vaccines. To contribute to pharmacovigilance and lessen the potential negative impact that vaccine hesitancy would have on immunization programs, we conducted a review of the...
Source: Adv Data - May 24, 2023 Category: Epidemiology Authors: Sara Eslait-Olaciregui Kevin Llin ás-Caballero David Pati ño-Manjarrés Thomas Urbina-Ariza Juan Fernando Cediel-Becerra Camilo Alberto Dom ínguez-Domínguez Source Type: research
A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis
Clin Exp Vaccine Res. 2023 Apr;12(2):172-175. doi: 10.7774/cevr.2023.12.2.172. Epub 2023 Apr 30.ABSTRACTCoronavirus disease 2019 (COVID-19) has become a part of our lives now and we have no more effective way of coping than a vaccine. COVID-19 is a disease that causes severe thrombosis outside the respiratory tract. Vaccines also protect us in this respect, but in some rare cases, thrombosis has been found to develop after vaccination (much less frequently than COVID-19). What was interesting in our case was that it showed how a disaster could happen under three factors that predispose to thrombosis. A 65-year-old female p...
Source: Atherosclerosis - May 22, 2023 Category: Cardiology Authors: Vecihe Bayrak Source Type: research
A case with prolonged headache after COVID-19 vaccination and later developed Bell's palsy
CONCLUSION: Reactivation of latent herpes virus has been suggested as one of the possible mechanisms underlying the phenomenon, but the causal pathophysiology related to the symptom needs further validation. Moreover, in the event of facial palsy post-vaccination, alternative diagnoses such as Guillain-Barre syndrome (GBS), Ramsey-Hunt syndrome, Lyme disease, trauma, central nervous system infection (CNS) infection, or stroke should also be considered.PMID:37198509
Source: Acta Neurologica Taiwanica - May 17, 2023 Category: Neurology Authors: Yi-Yang Hsiao Ling-Jun Liu Yo-Lin Lin Source Type: research
